nach oben

Erschienen in:

2023 | OriginalPaper | Buchkapitel

35. Hauterkrankungen

verfasst von : Prof. Dr. med. Hans Merk, PD Dr. med. Dr. Stephan R. Künzel, MBA

Erschienen in: Arzneiverordnungs-Report 2023

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Auf einen Blick

Verordnungsprofil Seit Jahren verändert sich das Verordnungsspektrum der zahlreicher dermatologischer Wirkstoffklassen nur marginal. Wie in den Vorjahren werden topische Glukokortikoide am häufigsten verordnet. Auf sie entfallen 43 von 100 Dermatikatagesdosen. Antimykotika und Psoriasismedikamente (jeweils 11 %), Medikamente bei aktinischer Keratose und Aknemedikamente (jeweils 7 %), Antiinfektiva und Warzenmedikamente (jeweils 5 %), Wundbehandlungsmedikamente und Antipruriginosa (jeweils 4 %) sowie Rosazeamedikamente (3 %) werden deutlich seltener verordnet. Aufgrund der dem Arzneiverordnungs-Report zugrunde liegenden Systematik werden in den Tabellen zu den Dermatikaverordnungen wesentliche Veränderungen in der Therapie chronisch-entzündlicher Dermatosen nicht vollständig abgebildet. Dies betrifft die Verwendung monoklonaler Antikörper (Biologika) und systemisch und topisch angewendeten JAK-Inhibitoren bei der Behandlung schwerer Fälle von atopischer Dermatitis, Psoriasis, Alopecia areata und Vitiligo (Lauffer und Biedermann 2022; Griffiths et al. 2021).

Abels C, Soeberdt M, Kilic A, Reich H, Knie U, Jourdan C, Schramm K, Heimstaedt-Muskett S, Masur C, Szeimies R (2021) A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial. Br J Dermatol 185:315–322PubMedPubMedCentralCrossRef

Adam DN, Gooderham MJ, Beecker JR, Hong CH, Jack CS, Jain V, Lansang P, Lynde CW, Papp KA, Prajapati VH, Turchin I, Yeung J (2023) Expert consensus on the systemic treatment of atopic dermatitis in special populations. J Eur Acad Dermatol Venereol 37(6):1135–1148PubMedCrossRef

Alsterholm M, Flytström I, Bergbrant IM, Faergemann J (2010) Fusidic acid-resistant staphylococcus aureus in impetigo contagiosa and secondarily infected atopic dermatitis. Acta Derm Venereol 90:52–57PubMedCrossRef

Amann PM, Merk HF, Baron JM (2014) Retinoide in der Dermatopharmakologie. Hautarzt 65:98–105PubMedCrossRef

Armstrong AW, Read C (2020) Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA 323:1945–1960PubMedCrossRef

Arzneimittelkommission der deutschen Ärzteschaft (2006) Psychiatrische Reaktionen nach Terninafin (Lamisil^®). Dtsch Arztebl 103:A3432

Arzneimittelkommission der deutschen Ärzteschaft (2013) Rhabdomyolyse nach Isotretinoin. Dtsch Arztebl 110:240

Arzneimittelkommission der deutschen Ärzteschaft (2019a) „Aus der UAW-Datenbank“: Rezidiv eines Morbus Crohn nach Behandlung einer atopischen Dermatitis mit Dupilumab. Dtsch Arztebl 116:A1919–A1920

Arzneimittelkommission der deutschen Ärzteschaft (2019b) Retinoide (Acitretin, Adapalen, Alitretinoin, Bexaroten, lsotretinoin, Tazaroten und Tretinoin) – Aktualisierungen zu Teratogenität und neuropsychiatrischen Erkrankungen. Drug Safety 50: (www.akdae.de)

Arzneimittelkommission der deutschen Ärzteschaft (2020) Brivudinhaltige Arzneimittel: Potenziell tödliche Toxizität von Fluoropyrimidinen bei der Anwendung kurz vor, gleichzeitig mit oder innerhalb von 4 Wochen nach Ende der Behandlung mit Brivudin. Drug Safety 31: (www.akdae.de)

Aszodi N, Thurau S, Seegräber M, de Bruin-Weller M, Wollenberg A (2019) Management of dupilumab-associated conjunctivitis in atopic dermatitis. J Dtsch Dermatol Ges 17:488–491PubMed

Atwan A, Ingram JR, Abbott R, Kelson MJ, Pickles T, Bauer A, Piguet V (2016) Oral fumaric acid esters for psoriasis: abridged Cochrane systematic review including GRADE assessments. Br J Dermatol 175:873–881PubMedPubMedCentralCrossRef

Bachelez H, Choon SE, Marrakchi S, Burden AD, Tsai TF, Morita A, Turki H, Hall DB, Shear M, Baum P, Padula SJ, Thoma C (2019) Inhibition of the Interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med 380:981–983PubMedCrossRef

Balak DMW, Fallah Arani S, Hajdarbegovic E, Hagemans CAF, Bramer WM, Thio HB, Neumann HAM (2016) Efficacy, effectiveness and safety of fumaric acid esters in the treatment of psoriasis: a systematic review of randomized and observational studies. Br J Dermatol 175:250–226PubMedCrossRef

Balak DMW, Hajdarbegovic E, Bramer WM, Neumann HAM, Thio HB (2017) Progressive mulrifocal leukencephalopathy associated wirh fumaric acid etsres treatment in psoriasis patients. J Eur Acad Dermatol Venereol 31:1475–1482PubMedCrossRef

Barajas-Nava LA, López-Alcalde J, Roqué i Figuls M, Solà I, Bonfill Cosp X (2013) Antibiotic prophylaxis for preventing burn wound infection. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD008738.pub2 CrossRefPubMed

Baron JM, Glatz M, Proksch E (2020) Optimal support of wound healing: new insights. Dermatology 236:593–600PubMedCrossRef

Bell-Syer SEM, Khan SM, Torgerson DJ (2012) Oral treatments for fungal infections of the skin of the foot. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD003584.pub2 CrossRefPubMedPubMedCentral

Blauvelt A, Reich K, Tsai TF, Tyring S, Vanaclocha F, Kingo K, Ziv M, Pinter A, Vender R, Hugot S, You R, Mi-lutinovic M, Thaçi D (2017a) Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol 76:60–69.e9PubMedCrossRef

Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB (2017b) Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 76:405–417PubMedCrossRef

Blauvelt A, Kempers S, Lain E, Schlesinger T, Tyring S, Forman S, Ablon G, Martin G, Wang H, Cutler DL, Fang J, Kwan MR (2021) Phase 3 Tirbanibulin for actinic keratosis group. Phase 3 trials of Tirbanibulin ointment for actinic keratosis. N Engl J Med 384(6):512–520PubMedCrossRef

Booij MT, van De Kerkhof PC (2011) Acitretin revisited in the era of biologics. J Dermatolog Treat 22:86–89PubMedCrossRef

Brodt HR (2013) Stille – Antibiotikatherapie. Klinik und Praxis der antiinfektiösen Behandlung, 12. Aufl. Schattauer, Stuttgart

Brück J, Dringen R, Amasuno A, Pau-Charles I, Ghoreschi K (2018) A review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis. Exp Dermatol 27:611–624PubMedCrossRef

Bundesministerium für Gesundheit (2015) Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL) ((Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) – Secukinumab) vom: 27. Nov. 2015. BAnz AT 29. Dez. 2015 B4)

Bundesministerium für Gesundheit (2017) Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL) ((Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) – Secukinumab (Neubewertung aufgrund neuer wissenschaftlicher Erkenntnisse)) vom: 17. Aug. 2017. BAnz AT 12. Sept. 2017 B2)

Bundesministerium für Gesundheit (2018) Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL) ((Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) – Guselkumab) vom: 17. Mai 2018. BAnz AT 4. Juli 2018 B2)

Bundesministerium für Gesundheit (2021) Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (Anlage XII – Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Guselkumab (neues Anwendungsgebiet: Psoriasis-Arthritis) vom: 20. Mai 2021. BAnz AT 29. Juni 2021 B5)

Bundesministerium für Gesundheit (2022) Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (Anlage XII – Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Tirbanibulin (Aktinische Keratose, Olsen-Grad I) BAnz AT 22. März 2022 B3

Cardwell LA, Alinia H, Moradi Tuchayi S, Feldman SR (2016) New developments in the treatment of rosacea – role of once-daily ivermectin cream. Clin Cosmet Investig Dermatol 9:71–77PubMedPubMedCentralCrossRef

Christoffers WA, Coenraads PJ, Svensson Å, Diepgen TL, Dickinson-Blok JL, Xia J, Williams HC (2019) Interventions for hand eczema. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD004055.pub2 CrossRefPubMedPubMedCentral

Chroni E, Monastirli A, Tsambaos D (2010) Neuromuscular adverse effects associated with systemic retinoid dermatotherapy: monitoring and treatment algorithm for clinicians. Drug Safety 33:25–34PubMedCrossRef

Clanner-Engelshofen BM, Bernhard D, Dargatz S, Flaig MJ, Gieler U, Kinberger M, Klövekorn W, Kuna AC, Läuchli S, Lehmann P, Nast A, Pleyer U, Schaller M, Schöfer H, Steinhoff M, Schwennesen T, Werner RN, Zierhut M, Reinholz M (2022) S2k-Leitlinie: Rosazea. J Dtsch Dermatol Ges 20:1147–1167PubMedCrossRef

Clerens I, Goossens A (2017) Allergic contact dermatitis caused by panthenol: a rare but relevant sensitizer. Contact Derm 76:122–123CrossRef

Conde JF, Yelverton CB, Balkrishnan R, Fleischer AB Jr, Feldman SR (2007) Managing rosacea: a review of the use of metronidazole alone and in combination with oral antibiotics. J Drugs Dermatol 6:495–498PubMed

Connor TH, Stoeckel M, Evrard J, Legator MS (1977) The contribution of metronidazole and two metabolites to the mutagenic activity detected in urine of treated humans and mice. Cancer Res 37:629–633PubMed

Cornejo CM, Jambusaria-Pahlajani A, Willenbrink TJ, Schmults CD, Arron ST, Ruiz ES (2020) Field cancerization: treatment. J Am Acad Dermatol 83:719–730PubMedCrossRef

Costa CS, Bagatin E, Martimbianco ALC, da Silva EMK, Lúcio MM, Magin P, Riera R (2018) Oral isotretinoin for acne. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD009435.pub2 CrossRefPubMedPubMedCentral

Crawford F, Hollis S (2007) Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev 3:CD1434. https://doi.org/10.1002/14651858.CD001434.pub2 CrossRef

Czaika VA, Zuberbier T (2015) Lokale Kombinationstherapie bei entzündlichen Dermatomykosen. Review zu den Therapieempfehlungen in nationalen und internationalen Leitlinien. Hautarzt 66:360–369PubMedCrossRef

Dall’Oglio F, D’Amico V, Nasca MR, Micali G (2012) Treatment of cutaneous warts: an evidence-based review. Am J Clin Dermatol 13:73–96PubMedCrossRef

Darkes MJM, Scott LJ, Goa KL (2003) Terbinafine. A review of its use in onychomycosis in adults. Am J Clin Dermatol 4:39–65PubMedCrossRef

Deutsche Dermatologische Gesellschaft (2016) Leitlinie zur Diagnostik und Therapie der Ichthyosen (Aktualisierung). AWMF-Leitlinien-Register Nr. 013/043, Entwicklungsstufe S1. Gültigkeit seit 18.06.2021 abgelaufen. https://www.awmf.org/leitlinien/detail/ll/013-043.html

Deutsche Dermatologische Gesellschaft et al (2015) Leitlinie Neurodermitis [atopisches Ekzem; atopische Dermatitis] Entwicklungsstufe: S2k [ICD 10: L20.8, L20.9, L28.0], AWMF-Registernummer: 013-027. Gültigkeit seit 30.03.2020 abgelaufen. https://www.awmf.org/uploads/tx_szleitlinien/013-027l_S2k_Neurodermitis_2020-06-abgelaufen.pdf

Dissemond J, Gerber V, Kramer A, Riepe G, Strohal R, Vasel-Biergans A, Eberlein T (2009) Praxisorientierte Expertenempfehlung zur Behandlung kritisch kolonisierter und lokal infizierter Wunden mit Polihexanid. WundManagement 2009:62–68

Dissemond J, Augustin M, Eming SA, Goerge T, Horn T, Karrer S, Schumann H, Stücker M (2014) Modern wound care – practical aspects of non-interventional topical treatment of patients with chronic wounds. J Dtsch Ges Dermatol. https://doi.org/10.1111/ddg.12351 CrossRef

Dittmann K, Schmidt T, Müller G, Cuny C, Holtfreter S, Troitzsch D, Pfaff P, Hübner NO (2019) Susceptibility of livestock-associated methicillin-resistant staphylococcus aureus (LA-MRSA) to chlorhexidine digluconate, octenidine dihydrochloride, polyhexanide, PVP-iodine and triclosan in comparison to hospital-acquired MRSA (HA-MRSA) and community-aquired MRSA (CA-MRSA): a standardized comparison. Antimicrob Resist Infect Control 8:122PubMedPubMedCentralCrossRef

Dréno B, Bettoli V, Ochsendorf F, Layton AM, Perez M, Dakovic R, Gollnick H (2014) Efficacy and safety of clindamycin phosphate 1.2%/tretinoin 0.025% formulation for the treatment of acne vulgaris: pooled analysis of data from three randomised, double-blind, parallel-group, phase III studies. Eur J Dermatol 24:201–209PubMedCrossRef

Drucker CR (2012) Update on topical antibiotics in dermatology. Dermatol Ther 25:6–11PubMedCrossRef

Dumville JC, Keogh SJ, Liu Z, Stubbs N, Walker RM, Fortnam M (2015a) Alginate dressings for treating pressure ulcers. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD011277.pub2 CrossRefPubMedPubMedCentral

Dumville JC, Stubbs N, Keogh SJ, Walker RM, Liu Z (2015b) Hydrogel dressings for treating pressure ulcers. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD011226.pub2 CrossRefPubMedPubMedCentral

Dumville JC, Gray TA, Walter CJ, Sharp CA, Page T, Macefield R, Blencowe N, Milne TK, Reeves BC, Blazeby J (2016) Dressings for the prevention of surgical site infection. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD003091.pub4 CrossRefPubMedPubMedCentral

Ebbelaar CCF, Venema AW, Van Dijk MR (2018) Topical Ivermectin in the treatment of papulopustular rosacea: a systematic review of evidence and clinical guideline recommendations. Dermatol Ther (Heidelb) 8:379–387PubMedCrossRef

Eberlein T, Assadian O (2010) Clinical use of polihexanide on acute and chronic wounds for antisepsis and decontamination. Skin Pharmacol Physiol 23(Suppl 1):45–51PubMedCrossRef

Ebner F, Heller A, Rippke F, Tausch I (2002) Topical use of dexpanthenol in skin disorders. Am J Clin Dermatol 3:427–433PubMedCrossRef

El-Gohary M, van Zuuren EJ, Fedorowicz Z, Burgess H, Doney L, Stuart B, Moore M, Little P (2014) Topical antifungal treatments for tinea cruris and tinea corporis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD009992.pub2 CrossRefPubMed

Erbagci Z (2004) Topical therapy for dermatophytoses. Should corticosteroids be included? Am J Clin Dermatol 5:375–384PubMedCrossRef

European Medicines Agency (2009) Committee on herbal medicinal products (HMPC) assessment report on Hamamelis virginiana L, Cortex; Hamamelis virginiana L, Folium, Hamamelis virginiana L. Folium et cortex aut ramunculus destillatum. http://www.ema.europa.eu/ema/. Zugegriffen: 28. Sept. 2022

European Medicines Agency (2015) Committee on herbal medicinal Produkts (HMPC) assessment report on Matricaria recutita L., flos and Matricaria recutita L., aetheroleum. http://www.ema.europa.eu/ema/. Zugegriffen: 28. Sept. 2022

Evans RM, Mangelsdorf DJ (2014) Nuclear receptors, RXR, and the Big Bang. Cell 157:255–266PubMedPubMedCentralCrossRef

Feng X, Xiong X, Ran Y (2017) Efficacy and tolerability of amorolfine 5% nail lacquer in combination with systemic antifungal agents for onychomycosis: a meta-analysis and systematic review. Dermatol Ther. https://doi.org/10.1111/dth.12457 CrossRefPubMed

Ference JD, Last AR (2009) Choosing topical corticosteroids. Am Fam Physician 79:135–140PubMed

Fjeld H, Lingaas E (2016) Polyhexanide – safety and efficacy as an antiseptic. Tidsskr Nor Laegeforen 136:707–711PubMedCrossRef

Fluhr JW, Degitz K (2010) Antibiotika, Azelainsäure und Benzoylperoxid in der topische Aknetherapie. J Dtsch Dermatol Ges 8(Suppl 1):S24–S30PubMed

Fölster-Holst R, Latussek E (2007) Synthetic tannins in dermatology – a therapeutic option in a variety of pediatric dermatoses. Pediatr Dermatol 24:296–301PubMedCrossRef

Food and Drug Administration (2014) FDA warns of rare but serious hypersensitivity reactions with certain over-the-counter topical acne products. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM402663.pdf. Zugegriffen: 28. Sept. 2022

Fowler J, Jarratt M, Moore A, Meadows K, Pollack A, Steinhoff M, Liu Y, Leoni M (2012) Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol 166:633–641PubMedPubMedCentralCrossRef

Francis NA, Ridd MJ, Thomas-Jones E, Butler CC, Hood K, Shepherd V, Marwick CA, Huang C, Longo M, Wootton M, Sullivan F, CREAM Trial Management Group (2017) Oral and topical antibiotics for clinically infected eczema in children: a pragmatic randomized controlled trial in ambulatory care. Ann Fam Med 15:124–130PubMedPubMedCentralCrossRef

Freimooser S, Traidl S, Werfel T (2022) Entwicklung von neuen topischen Substanzen zur Therapie der atopischen Dermatitis. Hautarzt 73:514–519CrossRef

Gaspari A, Tyring SK, Rosen T (2009) Beyond a decade of 5% imiquimod topical therapy. J Drugs Dermatol 8:467–474

Gemeinsamer Bundesausschuss (2021) Richtlinie des Gemeinsamen Bundesausschusses über die Verordnung von Arzneimitteln in der vertragsärztlichen Versorgung (Arzneimittel-Richtlinie/AM-RL) in der Fassung vom 18. Dezember 2008/22.Januar 2009 veröffentlicht im Bundesanzeiger 2009 Nr. 49a. https://www.g-ba.de/downloads/62-492-2565/AM-RL-2021-06-17_iK-2021-08-03_AT-02-08-2021-B5.pdf (Erstellt: 17. Juni 2021) (veröffentlicht im Bundesanzeiger (BAnz AT 2. Aug. 2021 B5) in Kraft getreten am 3. August 2021)

Gieselbach RJ, Muller-Hansma AH, Wijburg MT, de Bruin-Weller MS, van Oosten BW, Nieuwkamp DJ, Coenjaerts FE, Wattjes MP, Murk JL (2017) Progressive multifocal leukencephalopathy in patients treated with fumaric acid esters: a review of 19 cases. J Neurol 264:1155–1164PubMedCrossRef

Glenn CJ, Kobraei KB, Russo JJ (2011) New-onset psoriasis associated with adalimumab: a report of two cases. Dermatol Online J 17:15PubMedCrossRef

Gloor M (1982) Pharmakologie dermatologischer Externa. Springer, Berlin, Heidelberg, New YorkCrossRef

Gold LS, Papp K, Lynde C, Lain E, Gooderham M, Johnson S, Kerrouche N (2017) Treatment of rosacea with concomitant use of topical Ivermectin 1% cream and Brimonidine 0.33% gel: a randomized, vehicle-controlled study. J Drugs Dermatol 16:909–916PubMed

Gollnick HP, Draelos Z, Glenn MJ, Rosoph LA, Kaszuba A, Cornelison R, Gore B, Liu Y, Graeber M (2009) Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. Br J Dermatol 161:1180–1189PubMedCrossRef

Goreshi R, Samrao A, Ehst BD (2012) A double-blind, randomized, bilateral comparison of skin irritancy following application of the combination acne products clindamycin/tretinoin and benzoyl peroxide/adapalene. J Drugs Dermatol 11:1422–1426PubMed

Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C, Xia Y, Zhou B, Li S, Dooley LT, Goldstein NH, Menter A (2010) Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 362:118–128PubMedCrossRef

Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN (2021) Psoriasis. Lancet 397:1301–1315PubMedCrossRef

Grillo-Ardila CF, Angel-Müller E, Salazar-Díaz LC, Gaitán HG, Ruiz-Parra AI, Lethaby A (2014) Imiquimod for anogenital warts in non-immunocompromised adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD010389.pub2 CrossRefPubMedPubMedCentral

Grover C, Khurana A (2012) An update on treatment of onychomycosis. Mycoses 55:541–551PubMedCrossRef

Gupta AK, Cherman AM, Tyring SK (2005) Viral and nonviral uses of imiquimod: a review. J Cut Med Surg 8:338–352CrossRef

Gupta AK, Paquet M, Villanueva E, Brintnell W (2012) Interventions for actinic keratoses. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD004415.pub2 CrossRefPubMedPubMedCentral

Hahn C, Röseler S, Fritzsche R, Schneider R, Merk HF (1993) Allergic contact reaction to dexpanthenol: lymphocyte transformation test and evidence for microsomal-dependent metabolism of the allergen. Contact Dermat 28:81–83CrossRef

Hayden MK, Lolans K, Haffenreffer K, Avery TR, Kleinman K, Li H, Kaganov RE, Lankiewicz J, Moody J, Septimus E, Weinstein RA, Hickok J, Jernigan J, Perlin JB, Platt R, Huang SS (2016) Chlorhexidine and mupirocin susceptibility of methicillin-resistant staphylococcus aureus isolates in the REDUCE-MRSA trial. J Clin Microbiol 54:2735–2742PubMedPubMedCentralCrossRef

Hendriks AG, Keijsers RR, de Jong EM, Seyger MM, van de Kerkhof PC (2013a) Combinations of classical time-honoured topicals in plaque psoriasis: a systematic review. J Eur Acad Dermatol Venereol 27:399–410PubMedCrossRef

Hendriks AG, Keijsers RR, de Jong EM, Seyger MM, van de Kerkhof PC (2013b) Efficacy and safety of combinations of first-line topical treatments in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 27:931–951PubMedCrossRef

Hengge UR, Ruzicka T, Schartz RA, Cork MJ (2006) Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 54:1–15PubMedCrossRef

Hund M, Sinkgraven R, Rzany B (2004) Randomisierte, plazebokontrollierte klinische Doppelblindstudie zur Wirksamkeit und Verträglichkeit der oralen Therapie mit Methantheliniumbromid (Vagantin^®) bei fokaler Hyperhidrose. J Dtsch Dermatol Ges 2:343–349PubMedCrossRef

Jacobi A, Mayer A, Augustin M (2015) Keratolytics and emollients and their role in the therapy of psoriasis: a systematic review. Dermatol Ther 5:1–18CrossRef

Jansen MHE, Kessels JPHM, Nelemans PJ, Kouloubis N, Arits AHMM, van Pelt HPA, Quaedvlieg PJF, Essers BAB, Steijlen PM, Kelleners-Smeets NWJ, Mosterd K (2019) Randomized trial of four treatment approaches for actinic keratosis. N Engl J Med 380:935–946PubMedCrossRef

Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB (1999) Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 5:2006–2011PubMed

Ju HJ, Han JH, Kim MS, Lee SH, Shin JW, Choi M, Jeong KH, Han TY, Choi CW, Lee HJ, Oh SH, Lee SH, Kim DH, Shin J, Lee JH, Kim SS, Kang HY, Chang SE, Kim JS, Lee DY, Choi GS, Suh DH, Kim CY, Park CJ, Kim KH, Lee AY, Park CK, Lee MH, Bae JM (2021) The long-term risk of lymphoma and skin cancer did not increase after topical calcineurin inhibitor use and phototherapy in a cohort of 25,694 patients with vitiligo. J Am Acad Dermatol 84:1619–1627PubMedCrossRef

van de Kerkhof PC, Kragballe K, Segaert S, Lebwohl M, International Psoriasis Council (2011) Factors impacting the combination of topical corticosteroid therapies for psoriasis: perspectives from the International Psoriasis Council. J Eur Acad Dermatol Venereol 25:1130–1139PubMedCrossRef

Kim H, Alten R, Avedano L, Dignass A, Gomollón F, Greveson K, Halfvarson J, Irving PM, Jahnsen J, Lakatos PL, Lee J, Makri S, Parker B, Peyrin-Biroulet L, Schreiber S, Simoens S, Westhovens R, Danese S, Jeong JH (2020) The future of biosimilars: maximizing benefits across immune-mediated inflammatory diseases. Drugs 80:99–113PubMedPubMedCentralCrossRef

Koburger T, Hübner NO, Braun M, Siebert J, Kramer A (2010) Standardized comparison of antiseptic efficacy of triclosan, PVP-iodine, octenidine dihydrochloride, polyhexanide and chlorhexidine digluconate. J Antimicrob Chemother 65:1712–1719PubMedCrossRef

Koning S, van der Sande R, Verhagen AP, van Suijlekom-Smit LWA, Morris AD, Butler CC, Berger M, van der Wouden JC (2012) Interventions for impetigo. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD003261.pub3 CrossRefPubMedPubMedCentral

Koo JYM (2005) New developments in topical sequential therapy for psoriasis. Skin Therapy Lett 10:1–4PubMed

Kreijkamp-Kaspers S, Hawke K, Guo L, Kerin G, Bell-Syer SEM, Magin P, Bell-Syer SV, van Driel ML (2017) Oral antifungal medication for toenail onychomycosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD010031.pub2 CrossRefPubMedPubMedCentral

von Krogh G (1978) Topical treatment of penile condylomata acuminata with podophyllin, podophyllotoxin and colchicine. A comparative study. Acta Derm Venereol 58:163–168CrossRef

Kujath P, Michelsen A (2008) Wunden – von der Physiologie zum Verband. Dtsch Arztebl 105:239–248

Küster W, Bohnsack K, Rippke F, Upmeyer HJ, Groll S, Traupe H (1998) Efficacy of urea therapy in children with ichthyosis. A multicenter randomized, placebo-controlled, double-blind, semilateral study. Dermatology 196:217–222PubMedCrossRef

Kwok CS, Gibbs S, Bennett C, Holland R, Abbott R (2012) Topical treatments for cutaneous warts. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.cd001781.pub3 CrossRefPubMedPubMedCentral

Kyoreva M, Li Y, Hoosenally M, Hardman-Smart J, Morrison K, Tosi I, Tolaini M, Barinaga G, Stockinger B, Mrowietz U, Nestle FO, Smith CH, Barker JN, Di Meglio P (2021) CYP1A1 Enzymatic activity influences skin inflammation via regulation of the AHR pathway. J Invest Dermatol 141:1553–1563PubMedPubMedCentralCrossRef

Lachapelle JM (2014) A comparison of the irritant and allergenic properties of antiseptics. Eur J Dermatol 24:3–9PubMedCrossRef

Lam M, Zhu JW, Tadrous M, Drucker AM (2021) Association between topical calcineurin inhibitor use and risk of cancer, including lymphoma, keratinocyte carcinoma, and melanoma: a systematic review and meta-analysis. JAMA Dermatol 157:549–558PubMedCrossRef

Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C (2014) Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med 371:326–338PubMedCrossRef

Langley RG, Lebwohl M, Krueger GG, Szapary PO, Wasfi Y, Chan D, Hsu MC, You Y, Poulin Y, Korman N, Prinz JC, Reich K (2015) Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol 172:1371–1383PubMedCrossRef

Langley RG, Tsai TF, Flavin S, Song M, Randazzo B, Wasfi Y, Jiang J, Li S, Puig L (2018) Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol 178:114–123PubMedCrossRef

Langner A, Sheehan-Dare R, Layton A (2007) A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide (Duac) and erythromycin + zinc acetate (Zineryt) in the treatment of mild to moderate facial acne vulgaris. J Eur Acad Dermatol Venereol 21:311–319PubMedCrossRef

Lansdown AB, Mirastschijski U, Stubbs N, Scanlon E, Ågren MS (2007) Zinc in wound healing: theoretical, experimental, and clinical aspects. Wound Repair Regen 15:2–16PubMedCrossRef

Lauffer F, Biedermann T (2022) Einschätzungen zur Therapie der moderaten bis schweren atopischen Dermatitis mit Januskinaseinhibitoren. Hautarzt 73:520–528CrossRef

Layton AM, Schaller M, Homey B, Hofmann MA, Bewley AP, Lehmann P, Nohlgård C, Sarwer DB, Kerrouche N, Ma YM (2015) Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study. J Eur Acad Dermatol Venereol 29:2405–2410PubMedPubMedCentralCrossRef

Lohde H, Stahlmann R (Hrsg.) (2004): Nadifloxacin – irrationaler Einsatz eines Fluorchinolons zur lokalen Aknetherapie. Zeitschr Chemother 25: 27–29

Løkkevik E, Skovlund E, Reitan JB, Hannisdal E, Tanum G (1996) Skin treatment with Bepanthen cream versus no cream during radiotherapy. Acta Oncol 35:1021–1026PubMedCrossRef

Lopaschuk CR (2013) New approach to managing genital warts. Can Fam Physician 59:731–736PubMedPubMedCentral

Luger TA, Loske KD, Elsner P, Kapp A, Kerscher M, Korting HC, Krutmann J, Niedner R, Röcken M, Ruzicka T, Schwarz T (2004) Topische Dermatotherapie mit Glukokortikoiden – Therapeutischer Index. J Deut Dermatol Gesell 2:629–634CrossRef

Margosian E What’s coming down the psoriasis pipeline. American Academy of Dermatology Dermworld weekly. https://www.aad.org/dw/weekly (Erstellt: 1. Aug. 2021). Zugegriffen: 5. Aug. 2021

McClellan KJ, Noble S (2000) Topical metronidazole. A review of its use in rosacea. Am J Clin Dermatol 1:191–199PubMedCrossRef

McNeil JC, Hulten KG, Kaplan SL, Mason EO (2014) Decreased susceptibilities to retapamulin, mupirocin, and chlorhexidine among staphylococcus aureus isolates causing skin and soft tissue infections in otherwise healthy children. Antimicrob Agents Chemother 58:2878–2883PubMedPubMedCentralCrossRef

Medicines and Healthcare Products Regulatory Agency (MRHA) (2016) Brimonidine gel (Mirvaso): risk of exacerbation of rosacea. https://www.gov.uk/drug-safety-update/brimonidine-gel-mirvaso-risk-of-exacerbation-of-rosacea (Erstellt: 8. Nov. 2016)

Menezes de Padua CA, Schnuch A, Nink K, Pfahlberg A, Uter W (2008) Allergic contact dermatitis to topical drugs – epidemiological risk assessment. Pharmacoepidemiol Drug Safety 17:813–821CrossRef

Merk HF (2021) Hauttumoren im Visier. Teil 1: Klassische medikamentöse Behandlung. Teil 2: Fortschritte in der medikamentösen Therapie von Hauttumoren. Dtsch Apoth Z 161:36–46

Merk HF (2007) Topical diclofenac in the treatment of actinic keratoses. Int J Dermatol 46:12–18PubMedCrossRef

Moore ZEH, Cowman S (2013) Wound cleansing for pressure ulcers. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD004983.pub3 CrossRefPubMedPubMedCentral

Mrowietz U, Szepietowski JC, Loewe R, van de Kerkhof P, Lamarca R, Ocker WG, Tebbs VM, Pau-Charles I (2017) Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm(®)- and placebo-controlled trial (BRIDGE). Br J Dermatol 176:615–623PubMedCrossRef

Muller A, Talon D, Potier A, Belle E, Cappelier G, Bertrand X (2005) Use of intranasal mupirocin to prevent methicillin-resistant staphylococcus aureus infection in intensive care units. Crit Care 9:R246–R250PubMedPubMedCentralCrossRef

Müller C, Berensmeier A, Hamm H, Dirschka T, Reich K, Fischer T, Rzany B (2013) Efficacy and safety of methantheline bromide (Vagantin(®)) in axillary and palmar hyperhidrosis: results from a multicenter, randomized, placebo-controlled trial. J Eur Acad Dermatol Venereol 27:1278–1284PubMedCrossRef

Nast A, Altenburg A, Augustin M, Boehncke WH, Härle P, Klaus J, Koza J, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Schlaeger M, Schmid-Ott G, Sebastian M, von Kiedrowski R, Weberschock T, Dressler C (2021) S3-Leitlinie Therapie der Psoriasis vulgaris AWMF-Register-Nr.: 013–001 mit Appendix. Stand: 19.02.2021 , gültig bis 30.09.2022. https://www.awmf.org/leitlinien/detail/ll/013-001.html

Nguyen ED, Gabel CK, Kroshinsky D (2021) Assessing the incidence of skin and soft tissue infection in patients on biologics. J Am Acad Dermatol 85:604–610PubMedCrossRef

Nieuwkamp DJ, Murk JL, van Oosten BW, Cremers CH, Killestein J, Viveen MC, Van Hecke W, Frijlink DW, Wattjes MP (2015) PML in a patient without severe lymphocytopenia receiving dimethyl fumarate. N Engl J Med 372:1474–1476PubMedCrossRef

Nímia HH, Carvalho VF, Isaac C, Souza FÁ, Gemperli R, Paggiaro AO (2019) Comparative study of Silver Sulfadiazine with other materials for healing and infection prevention in burns: a systematic review and meta-analysis. Burns 45:282–292PubMedCrossRef

O’Meara S, Cullum N, Nelson EA, Dumville JC (2012) Compression for venous leg ulcers. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD000265.pub3 CrossRefPubMedPubMedCentral

O’Meara S, Al-Kurdi D, Ologun Y, Ovington LG, Martyn-St JM, Richardson R (2014) Antibiotics and antiseptics for venous leg ulcers. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD003557.pub5 CrossRefPubMedPubMedCentral

Paller AS, Fölster-Holst R, Chen SC, Diepgen TL, Elmets C, Margolis DJ, Pollock BH (2020) No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. J Am Acad Dermatol 83:375–381PubMedCrossRef

Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, Hu C, Stevens RM, Day RM, Gordon KB, Korman NJ, Griffiths CE (2015) Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (efficacy and safety trial evaluating the effects of Apremilast in psoriasis [ESTEEM] 1). J Am Acad Dermatol 73:37–49PubMedCrossRef

Patry J, Blanchette V (2017) Enzymatic debridement with collagenase in wounds and ulcers: a systematic review and meta-analysis. Int Wound J 14:1055–1065PubMedPubMedCentralCrossRef

Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, Crowley J, Hu C, Stevens RM, Shah K, Day RM, Girolomoni G, Gottlieb AB (2015) Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ES-TEEM 2). Br J Dermatol 173:1387–1399PubMedCrossRef

Penso L, Dray-Spira R, Weill A, Vegas PL, Zureik M, Sbidian E (2021) Association between biologics use and risk of serious infection in patients with psoriasis. JAMA Dermatol. https://doi.org/10.1001/jamadermatol.2021.2599 CrossRefPubMedPubMedCentral

Raharja A, Mahil SK, Barker JN (2021) Psoriasis: a brief overview. Clin Med (Lond) 21:170–173PubMedCrossRef

Ramos-e-Silva M, Lima CM, Schechtman R, Trope MB, Carneiro S (2012) Systemic mycoses in immunodepressed patients (AIDS). Clin Dermatol 30:616–627PubMedCrossRef

Rashaan ZM, Krijnen P, Klamer RR, Schipper IB, Dekkers OM, Breederveld RS (2014) Nonsilver treatment vs. silver sulfadiazine in treatment of partial-thickness burn wounds in children: a systematic review and meta-analysis. Wound Repair Regen 22:473–482PubMedCrossRef

Rathi SK, D’Souza P (2012) Rational and ethical use of topical corticosteroids based on safety and efficacy. Indian J Dermatol 57:251–259PubMedPubMedCentralCrossRef

Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, Day RM, Goncalves J, Shah K, Piguet V, Soung J (2017a) The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol 31:507–517PubMedCrossRef

Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB (2017b) Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol 76:418–431PubMedCrossRef

Rendon A, Schäkel K (2019) Psoriasis pathogenesis and treatment. Int J Mol Sci 20:1475PubMedPubMedCentralCrossRef

Ribeiro CTD, Dias FAL, Fregonezi GAF (2022) Hydrogel dressings for venous leg ulcers. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD010738.pub2 CrossRefPubMedPubMedCentral

Ring J, Fröhlich HH (1985) Wirkstoffe in der dermatologischen Therapie, 2. Aufl. Springer, Berlin Heidelberg, New YorkCrossRef

Rotta I, Sanchez A, Gonçalves PR, Otuki MF, Correr CJ (2012) Efficacy and safety of topical antifungals in the treatment of dermatomycosis: a systematic review. Br J Dermatol 166:927–933PubMedCrossRef

Saco M, Howe N, Nathoo R, Cherpelis B (2016) Comparing the efficacies of alginate, foam, hydrocolloid, hydrofiber, and hydrogel dressings in the management of diabetic foot ulcers and venous leg ulcers: a systematic review and meta-analysis examining how to dress for success. Dermatol Online J 22:13030/qt7ph5v17zPubMedCrossRef

Samrao A, Cockerell CJ (2013) Pharmacotherapeutic management of actinic keratosis: focus on newer topical agents. Am J Clin Dermatol 14:273–237PubMedCrossRef

Saraswat A (2014) Ethical use of topical corticosteroids. Indian J Dermatol 59:469–472PubMedPubMedCentralCrossRef

Sawyer LM, Cornic L, Levin LÅ, Gibbons C, Møller AH, Jemec GB (2019) Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. J Eur Acad Dermatol Venereol 33:355–366PubMedCrossRef

Sbidian E, Chaimani A, Garcia-Doval I, Doney L, Dressler C, Hua C, Hughes C, Naldi L, Afach S, Le Cleach L (2022) Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD011535.pub5 CrossRefPubMedPubMedCentral

Schaller M, Friedrich M, Papini M, Pujol RM, Veraldi S (2016) Topical antifungal-corticosteroid combination therapy for the treatment of superficial mycoses: conclusions of an expert panel meeting. Mycoses 59:365–373PubMedCrossRef

Schöfer H, Simonsen L (2010) Fusidic acid in dermatology: an updated review. Eur J Dermatol 20:6–15PubMedCrossRef

Senner S, Eicher L, Aszodi N, Prinz JC, French LE, Wollenberg A (2020) Psoriasis bei Dupilumab-behandeltem atopischem Ekzem. Hautarzt 71:383–386PubMedCrossRef

Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR (2011) Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol 67:e179–e185PubMedCrossRef

Singal A, Khanna D (2011) Onychomycosis: diagnosis and management. Indian J Dermatol Venereol Leprol 77:659–672PubMedCrossRef

Singh S, Fatima Z, Hameed S (2015) Predisposing factors endorsing Candida infections. Infez Med 23:211–223PubMed

Solares CA, Batra PS, Hall GS, Citardi MJ (2006) Treatment of chronic rhinosinusitis exacerbations due to methicillin-resistant staphylococcus aureus with mupirocin irrigations. Am J Otolaryngol 27:161–165PubMedCrossRef

Steeb T, Wessely A, Petzold A, Brinker TJ, Schmitz L, Leiter U, Garbe C, Schöffski O, Berking C, Heppt MV (2021) Evaluation of long-term clearance rates of interventions for actinic keratosis: a systematic review and network meta-analysis. JAMA Dermatol. https://doi.org/10.1001/jamadermatol.2021.2779 CrossRefPubMedPubMedCentral

Gold SL, Kircik L, Fowler J, Jackson JM, Tan J, Draelos Z, Fleischer A, Appell M, Steinhoff M, Lynde C, Sugarman J, Liu H, Jacovella J (2014) Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. J Drugs Dermatol 13:1380–1386

Sticherling M, Mrowietz U, Augustin M, Thaçi D, Melzer N, Hentschke C, Kneidl J, Sieder C, Reich K (2017) Secukinumab is superior to fumaric acid esters in treating subjects with moderate to severe plaque psoriasis who are Naïve to systemic treatments: results from the randomized controlled PRIME trial. Br J Dermatol Br J Dermatol 177:1024–1032PubMedCrossRef

Stockfleth E, Beti H, Orasan R, Grigorian F, Mescheder A, Tawfik H, Thielert C (2008) Topical polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial. Br J Dermatol 158:1329–1338PubMedCrossRef

Stockfleth E, Kerl H, Zwingers T, Willers C (2011) Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol 165:1101–1108PubMedCrossRef

Strober B, Gottlieb AB, Sherif B, Mollon P, Gilloteau I, McLeod L, Fox T, Mordin M, Gnanasakthy A, Papavassilis C, Lebwohl MG (2017) Secukinumab sustains early patient-reported outcome benefits through 1 year: results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. J Am Acad Dermatol 76:655–661PubMedCrossRef

Subissi A, Monti D, Togni G, Mailland F (2010) Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent. Drugs 70:2133–2152PubMedCrossRef

Taieb A, Ortonne JP, Ruzicka T, Roszkiewicz J, Berth-Jones J, Peirone MH, Jacovella J (2015) Superiority of ivermectin 1% cream over metronidazole 0·75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol 172:1103–1110PubMedCrossRef

Tatti S, Swinehart JM, Thielert C, Tawfik H, Mescheder A, Beutner KR (2008) Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol 111:1371–1379PubMedCrossRef

Thaçi D, Schöfer H (2005) Topische Antibiotika zur Therapie von Hautinfektionen. Hautarzt 56:381–396PubMedCrossRef

Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, Ziv M, Pinter A, Hugot S, You R, Milutinovic M (2015) Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol 73:400–409PubMedCrossRef

Thaçi D, Pinter A, Sebastian M, Termeer C, Sticherling M, Gerdes S, Wegner S, Krampe S, Bartz H, Rausch C, Mensch A, Eyerich K (2019) Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS). Br J Dermatol. https://doi.org/10.1111/bjd.18696 CrossRefPubMedPubMedCentral

Thiboutot D, Dréno B, Sanders V, Rueda MJ, Gollnick H (2020) Changes in the management of acne: 2009–2019. J Am Acad Dermatol 82:1268–1269PubMedCrossRef

Thiboutot DM, Dréno B, Abanmi A, Alexis AF, Araviiskaia E, Barona Cabal MI, Bettoli V, Casintahan F, Chow S, da Costa A, El Ouazzani T, Goh CL, Gollnick HPM, Gomez M, Hayashi N, Herane MI, Honeyman J, Kang S, Kemeny L, Kubba R, Lambert J, Layton AM, Leyden JJ, López-Estebaranz JL, Noppakun N, Ochsendorf F, Oprica C, Orozco B, Perez M, Piquero-Martin J, See JA, Suh DH, Tan J, Lozada VT, Troielli P, Xiang LF (2018) Practical management of acne for clinicians: an international consensus from the Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 78(2 Suppl 1):S1–S23.e1PubMedCrossRef

Thiboutot DM, Weiss J, Bucko A, Eichenfield L, Jones T, Clark S, Liu Y, Graeber M, Kang S, Adapalene-BPO Study Group (2007) Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol 57:791–799PubMedCrossRef

Thurgar E, Barton S, Karner C, Edwards SJ (2016) Clinical effectiveness and cost-effectiveness of interventions for the treatment of anogenital warts: systematic review and economic evaluation. Health Technol Assess 20(v–vi):1–486PubMedCentralCrossRef

Udompataikul M, Limpa-o-vart D (2012) Comparative trial of 5% dexpanthenol in water-in-oil formulation with 1% hydrocortisone ointment in the treatment of childhood atopic dermatitis: a pilot study. J Drugs Dermatol 11:366–374PubMed

Valente Duarte de Sousa IC (2014) Novel pharmacological approaches for the treatment of acne vulgaris. Expert Opin Investig Drugs 23:1389–1410PubMedCrossRef

Wananukul S, Limpongsanuruk W, Singalavanija S, Wisuthsarewong W (2006) Comparison of dexpanthenol and zinc oxide ointment with ointment base in the treatment of irritant diaper dermatitis from diarrhea: a multicenter study. J Med Assoc Thai 89:1654–1658PubMed

Werfel T, Heratizadeh A, Aberer W, Ahrens F, Augustin M, Biedermann T, Diepgen T, Fölster-Holst R, Kahle J, Kapp A, Nemat K, Peters E, Schlaeger M, Schmid-Grendelmeier P, Schmitt J, Schwennesen T, Staab D, Traidl-Hoffmann C, Werner R, Wollenberg A, Worm M, Ott H (2021) Update „Systemic treatment of atopic dermatitis“ of the S2k-guideline on atopic dermatitis. J Dtsch Dermatol Ges 19:151–168PubMed

Werner RN, Westfechtel L, Dressler C, Nast A (2017) Self-administered interventions for anogenital warts in immunocompetent patients: a systematic review and meta-analysis. Sex Transm Infect 93:155–161PubMedCrossRef

Wheat CM, Bickley RJ, Hsueh YH, Cohen BA (2017) Current trends in the use of two combination antifungal/corticosteroid creams. J Pediatr 186:192–195PubMedCrossRef

Williams H (2002) New treatments for topic dermatitis. Brit Med J 324:1533–1534PubMedPubMedCentralCrossRef

Williamson DA, Carter GP, Howden BP (2017) Current and emerging topical antibacterials and antiseptics: agents, action, and resistance patterns. Clin Microbiol Rev 30(3):827–860PubMedPubMedCentralCrossRef

Willy C, Stichling M, Müller M, Gatzer R, Kramer A, Vogt D (2016) Akute Maßnahmen beim „limb salvage“ – Prozedere Teil 2. Debridement, Lavagetechniken und antiinfektiöse Strategien. Unfallchirurg 119:388–399PubMedCrossRef

Wohlrab J (2016) Topika und deren Einsatz in der Dermatologie. J Dtsch Dermatol Ges 14:1061–1071PubMed

Wollenberg A, Christen-Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M, Vestergaard C, Seneschal J, Werfel T, Cork MJ, Kunz B, Fölster-Holst R, Trzeciak M, Darsow U, Szalai Z, Deleuran M, von Kobyletzki L, Barbarot S, Heratizadeh A, Gieler U, Hijnen DJ, Weidinger S, De Raeve L, Svensson Å, Simon D, Stalder JF, Ring J (2020) Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol 34:2717–2744PubMedCrossRef

Wong RK, Bensadoun RJ, Boers-Doets CB, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Lacouture ME (2013) Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. Support Care Cancer 21:2933–2948PubMedCrossRef

Worret WI, Fluhr JW (2006) Acne therapy with topical benzoyl peroxide, antibiotics and azelaic acid. J Dtsch Dermatol Ges 4:293–300PubMedCrossRef

Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, Bowe WP, Graber EM, Harper JC, Kang S, Keri JE, Leyden JJ, Reynolds RV, Silverberg NB, Gold SLF, Tollefson MM, Weiss JS, Dolan NC, Sagan AA, Stern M, Boyer KM, Bhushan R (2016) Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 74:945–973.e33PubMedCrossRef

Zhu TH, Nakamura M, Abrouk M, Farahnik B, Koo J, Bhutani T (2016) Demyelinating disorders secondary to TNF-inhibitor therapy for the treatment of psoriasis: a review. J Dermatolog Treat 2:1–8

van Zuuren EJ, Fedorowicz Z, Arents BWM (2017) Emollients and moisturizers for eczema: abridged Cochrane systematic review including GRADE assessments. Br J Dermatol 177:1256–1271PubMedCrossRef

van Zuuren EJ, Fedorowicz Z, Tan J, van der Linden MMD, Arents BWM, Carter B, Charland L (2019) Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. Br J Dermatol 181:65–79PubMedPubMedCentralCrossRef

van Zuuren EJ, Arents BWM, van der Linden MMD, Vermeulen S, Fedorowicz Z, Tan J (2021) Rosacea: new concepts in classification and treatment. Am J Clin Dermatol 22:457–465PubMedPubMedCentralCrossRef

Titel: Hauterkrankungen
verfasst von: Prof. Dr. med. Hans Merk
PD Dr. med. Dr. Stephan R. Künzel, MBA
Verlag: Springer Berlin Heidelberg
Buch: Arzneiverordnungs-Report 2023
Print ISBN: 978-3-662-68370-5

Electronic ISBN: 978-3-662-68371-2

Copyright-Jahr: 2023
DOI: https://doi.org/10.1007/978-3-662-68371-2_35

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen